Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
Clinical treatment options for human cholangiocarcinoma (CC) are limited. c-MET, a high-affinity receptor for hepatocyte growth factor (HGF), is deregulated in many cancers. Its role in cholangiocarcinogenesis remains unclear. In current study, 23 corresponding tumor- and non-tumor tissues, taken fr...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2019]
|
| In: |
Cell death & disease
Year: 2019, Jahrgang: 10, Heft: 3 |
| ISSN: | 2041-4889 |
| DOI: | 10.1038/s41419-019-1460-1 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1038/s41419-019-1460-1 Verlag, Volltext: https://www.nature.com/articles/s41419-019-1460-1 
|
| Verfasserangaben: | Kai Wei, Mao Li, Margot Zöller, Meng Wang, Arianeb Mehrabi and Katrin Hoffmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1666663891 | ||
| 003 | DE-627 | ||
| 005 | 20230426220908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190604s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41419-019-1460-1 |2 doi | |
| 035 | |a (DE-627)1666663891 | ||
| 035 | |a (DE-599)KXP1666663891 | ||
| 035 | |a (OCoLC)1341227431 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wei, Kai |d 1988- |e VerfasserIn |0 (DE-588)1187761818 |0 (DE-627)1666665223 |4 aut | |
| 245 | 1 | 0 | |a Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma |c Kai Wei, Mao Li, Margot Zöller, Meng Wang, Arianeb Mehrabi and Katrin Hoffmann |
| 264 | 1 | |c [2019] | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.06.2019 | ||
| 520 | |a Clinical treatment options for human cholangiocarcinoma (CC) are limited. c-MET, a high-affinity receptor for hepatocyte growth factor (HGF), is deregulated in many cancers. Its role in cholangiocarcinogenesis remains unclear. In current study, 23 corresponding tumor- and non-tumor tissues, taken from patients with intrahepatic (iCC) and perihilar cholangiocarcinoma (pCC), who underwent liver resection, were analyzed. The relationship of clinicopathological features and c-MET, as well as c-jun N-terminal kinase (JNK) was evaluated. The anti-tumor effects of Tivantinib, a small-molecule inhibitor with potent activity against the c-MET kinase, was investigated in three human CC cell lines, namely HUCC-T1, TFK-1, and EGI-1. In comparison with the results obtained in non-tumor tissue samples, c-MET was overexpressed in 91.3 % of tumor tissues (p < 0.01). The JNK expression was higher in tumor tissue compared with the corresponding non-tumor tissue sample in 17.4% patients (p < 0.01). The inhibition of aberrant c-MET expression in human CC cell lines was achieved by blocking the phosphorylation of c-MET with Tivantinib. Notable losses in cell viability and colony-forming capability were detected (p < 0.01). Synergistic activation of the JNK/c-jun pathway was demonstrated after Tivantinib treatment. Knockdown of the JNK by siRNA or competitive binding of c-MET receptor by stimulation with HGF-antagonized anti-tumor effects of Tivantinib was observed. Our data suggest that inhibition of c-MET could be a possible alternative approach for the treatment of human CC, for which Tivantinib may an effective inhibitor. The synergistic activation of the JNK/c-jun pathway contributed to the elevated apoptosis in CC cells via treatment with Tivantinib. | ||
| 700 | 1 | |a Li, Mao |d 1989- |e VerfasserIn |0 (DE-588)1187762121 |0 (DE-627)1666665967 |4 aut | |
| 700 | 1 | |a Zöller, Margot |d 1943- |e VerfasserIn |0 (DE-588)1071580337 |0 (DE-627)826058647 |0 (DE-576)433167572 |4 aut | |
| 700 | 1 | |a Mehrabi, Arianeb |d 1967- |e VerfasserIn |0 (DE-588)137664583 |0 (DE-627)594829763 |0 (DE-576)304831263 |4 aut | |
| 700 | 1 | |a Hoffmann, Katrin |d 1980- |e VerfasserIn |0 (DE-588)131774417 |0 (DE-627)513946950 |0 (DE-576)252913078 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell death & disease |d London [u.a.] : Nature Publishing Group, 2010 |g 10(2019,3) Artikel-Nummer 231, Seite 1-13, 13 Seiten |h Online-Ressource |w (DE-627)620145250 |w (DE-600)2541626-1 |w (DE-576)319429059 |x 2041-4889 |7 nnas |a Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |g number:3 |g extent:13 |a Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41419-019-1460-1 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41419-019-1460-1 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190604 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 131774417 |a Hoffmann, Katrin |m 131774417:Hoffmann, Katrin |d 910000 |d 910200 |e 910000PH131774417 |e 910200PH131774417 |k 0/910000/ |k 1/910000/910200/ |p 6 |y j | ||
| 998 | |g 137664583 |a Mehrabi, Arianeb |m 137664583:Mehrabi, Arianeb |d 910000 |d 910200 |e 910000PM137664583 |e 910200PM137664583 |k 0/910000/ |k 1/910000/910200/ |p 5 | ||
| 998 | |g 1071580337 |a Zöller, Margot |m 1071580337:Zöller, Margot |d 910000 |d 910200 |e 910000PZ1071580337 |e 910200PZ1071580337 |k 0/910000/ |k 1/910000/910200/ |p 3 | ||
| 998 | |g 1187762121 |a Li, Mao |m 1187762121:Li, Mao |d 910000 |d 910200 |e 910000PL1187762121 |e 910200PL1187762121 |k 0/910000/ |k 1/910000/910200/ |p 2 | ||
| 998 | |g 1187761818 |a Wei, Kai |m 1187761818:Wei, Kai |d 50000 |e 50000PW1187761818 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1666663891 |e 3480891810 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"13 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma","title":"Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma"}],"person":[{"family":"Wei","role":"aut","given":"Kai","display":"Wei, Kai"},{"display":"Li, Mao","role":"aut","given":"Mao","family":"Li"},{"display":"Zöller, Margot","given":"Margot","role":"aut","family":"Zöller"},{"display":"Mehrabi, Arianeb","given":"Arianeb","role":"aut","family":"Mehrabi"},{"display":"Hoffmann, Katrin","family":"Hoffmann","role":"aut","given":"Katrin"}],"recId":"1666663891","name":{"displayForm":["Kai Wei, Mao Li, Margot Zöller, Meng Wang, Arianeb Mehrabi and Katrin Hoffmann"]},"origin":[{"dateIssuedDisp":"[2019]","dateIssuedKey":"2019"}],"id":{"doi":["10.1038/s41419-019-1460-1"],"eki":["1666663891"]},"note":["Gesehen am 04.06.2019"],"relHost":[{"title":[{"title_sort":"Cell death & disease","title":"Cell death & disease"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Cell death and disease"}],"note":["Gesehen am 26.02.10"],"pubHistory":["1.2010 -"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"eki":["620145250"],"zdb":["2541626-1"],"issn":["2041-4889"]},"origin":[{"dateIssuedKey":"2010","publisher":"Nature Publishing Group","dateIssuedDisp":"2010-","publisherPlace":"London [u.a.]"}],"part":{"text":"10(2019,3) Artikel-Nummer 231, Seite 1-13, 13 Seiten","extent":"13","volume":"10","issue":"3","year":"2019"},"recId":"620145250","disp":"Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinomaCell death & disease"}]} | ||
| SRT | |a WEIKAILIMATARGETINGC2019 | ||